UNSPSC 51282921: Gatifloxacin

This classification denotes a quinolone antibiotic with the molecular formula 2C19H22FN3O4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, L4618BD7KJ chemically known as (+/-)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate but generally known as gatifloxacin, which bears US NIH Compound Identifier 5379. European Medicines Agency schedules Gatifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13952MIG.

UNSPSC 51282921 Gatifloxacin is a Commodity code that classifies individual pharmaceutical products, but the recent state and local contract records show little activity aligned with this specific antibiotic. The two opportunities posted under this code actually cover different pharmaceutical categories: one involves an awarded piggyback contract through a cooperative purchasing vehicle for broad-spectrum antibiotics (Doxycycline and Ciprofloxacin), and the other addresses naloxone and drug deactivation systems for community health. State and local health departments and county public health authorities use codes in this family to procure medications for emergency response, public health programs, and institutional supply chains, typically through cooperative purchasing consortia, IFB processes, and piggyback awards on statewide contracts.

The Illinois Department of Public Health awarded a $2,999,999.11 multi-year pharmaceutical supply contract to Chartwell Rx LLC through MMCAP Infuse on August 28, 2026 via an IFB process for antibiotic inventory, while Seminole County, Florida posted an IFB on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually. Recent activity reflects procurement by state health departments and county public health agencies concentrated in Illinois and Florida. The mismatch between the Gatifloxacin code's nominal scope and the recent opportunities suggests either that this code sees limited directed solicitation for this specific antibiotic, or that state and local procurement offices are tagging broader pharmaceutical supply categories under it. Business development professionals should verify current sourcing patterns with issuing agencies before pursuing this code — the recent record does not demonstrate active, regular demand for Gatifloxacin specifically.